MX2020007081A - Peptidos terapeuticos y metodos para tratar enfermedad relacionada con la autoinmunidad. - Google Patents
Peptidos terapeuticos y metodos para tratar enfermedad relacionada con la autoinmunidad.Info
- Publication number
- MX2020007081A MX2020007081A MX2020007081A MX2020007081A MX2020007081A MX 2020007081 A MX2020007081 A MX 2020007081A MX 2020007081 A MX2020007081 A MX 2020007081A MX 2020007081 A MX2020007081 A MX 2020007081A MX 2020007081 A MX2020007081 A MX 2020007081A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- peptides
- cells
- materials
- diabetes
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 8
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 5
- 230000005784 autoimmunity Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 101150013553 CD40 gene Proteins 0.000 abstract 6
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract 6
- 239000000463 material Substances 0.000 abstract 4
- 201000001320 Atherosclerosis Diseases 0.000 abstract 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 3
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 abstract 2
- 108010027279 Facilitative Glucose Transport Proteins Proteins 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 230000001363 autoimmune Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 230000028709 inflammatory response Effects 0.000 abstract 2
- 230000002452 interceptive effect Effects 0.000 abstract 2
- 208000011594 Autoinflammatory disease Diseases 0.000 abstract 1
- 238000008214 LDL Cholesterol Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862614262P | 2018-01-05 | 2018-01-05 | |
| US16/184,129 US20190194290A1 (en) | 2010-10-19 | 2018-11-08 | Methods for preventing, modulating and/or reducing cardiovascular disease |
| PCT/US2019/012425 WO2019136307A1 (en) | 2018-01-05 | 2019-01-04 | Therapeutic peptides and methods for treating autoimmune related disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007081A true MX2020007081A (es) | 2020-10-28 |
Family
ID=67144298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007081A MX2020007081A (es) | 2018-01-05 | 2019-01-04 | Peptidos terapeuticos y metodos para tratar enfermedad relacionada con la autoinmunidad. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3735260B1 (https=) |
| JP (2) | JP7511242B2 (https=) |
| CN (2) | CN119157997A (https=) |
| AU (1) | AU2019205328B2 (https=) |
| BR (1) | BR112020013716A2 (https=) |
| CA (1) | CA3086193A1 (https=) |
| MX (1) | MX2020007081A (https=) |
| SG (1) | SG11202006494VA (https=) |
| WO (1) | WO2019136307A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190263888A1 (en) | 2010-10-19 | 2019-08-29 | Op-T Llc | Therapeutic peptides and methods for treating autoimmune related disease |
| ES2957957T3 (es) | 2010-10-19 | 2024-01-30 | Op T Llc | Péptidos para modular la actividad de linfocitos T y usos de los mismos |
| US11793854B2 (en) | 2019-03-21 | 2023-10-24 | Op-T Llc | Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction |
| JP2022540731A (ja) * | 2019-07-12 | 2022-09-16 | オーピー－ティー エルエルシー | ペプチドおよび疾患の治療方法 |
| EP4135742A2 (en) * | 2020-04-17 | 2023-02-22 | Op-T Llc | Bioactive peptides and methods of use thereof |
| WO2021231898A2 (en) * | 2020-05-14 | 2021-11-18 | Op-T Llc | Nanoparticle compositions and uses thereof |
| WO2022036495A1 (en) * | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| CN115807071B (zh) * | 2022-09-02 | 2025-09-26 | 宁夏医科大学 | 检测试剂在制备2型糖尿病伴动脉粥样硬化诊断工具中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7495090B2 (en) * | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
| WO2005006949A2 (en) * | 2003-07-07 | 2005-01-27 | Wagner David H | Methods for predicting development of auto-immune diseases and treatment of same |
| US7449200B2 (en) * | 2006-04-17 | 2008-11-11 | Gp Medical, Inc. | Nanoparticles for protein/peptide delivery and delivery means |
| ES2957957T3 (es) * | 2010-10-19 | 2024-01-30 | Op T Llc | Péptidos para modular la actividad de linfocitos T y usos de los mismos |
| JP6285923B2 (ja) * | 2012-06-22 | 2018-02-28 | トラスティーズ・オブ・ダートマス・カレッジ | 新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用 |
| EP3123176A4 (en) * | 2014-03-23 | 2018-04-25 | The Regents of the University of Colorado | Diagnosis of multiple sclerosis in human and animal subjects |
-
2019
- 2019-01-04 BR BR112020013716-2A patent/BR112020013716A2/pt unknown
- 2019-01-04 AU AU2019205328A patent/AU2019205328B2/en active Active
- 2019-01-04 JP JP2020557124A patent/JP7511242B2/ja active Active
- 2019-01-04 WO PCT/US2019/012425 patent/WO2019136307A1/en not_active Ceased
- 2019-01-04 CN CN202411324616.4A patent/CN119157997A/zh active Pending
- 2019-01-04 SG SG11202006494VA patent/SG11202006494VA/en unknown
- 2019-01-04 CN CN201980017176.9A patent/CN111801110B/zh active Active
- 2019-01-04 EP EP19736089.4A patent/EP3735260B1/en active Active
- 2019-01-04 CA CA3086193A patent/CA3086193A1/en active Pending
- 2019-01-04 MX MX2020007081A patent/MX2020007081A/es unknown
-
2024
- 2024-06-17 JP JP2024097199A patent/JP2024123100A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN119157997A (zh) | 2024-12-20 |
| CN111801110B (zh) | 2024-10-18 |
| EP3735260B1 (en) | 2026-03-04 |
| WO2019136307A1 (en) | 2019-07-11 |
| AU2019205328B2 (en) | 2025-04-03 |
| EP3735260A1 (en) | 2020-11-11 |
| JP2021510174A (ja) | 2021-04-15 |
| SG11202006494VA (en) | 2020-08-28 |
| CN111801110A (zh) | 2020-10-20 |
| CA3086193A1 (en) | 2019-07-11 |
| JP7511242B2 (ja) | 2024-07-05 |
| BR112020013716A2 (pt) | 2020-12-22 |
| EP3735260A4 (en) | 2021-12-08 |
| JP2024123100A (ja) | 2024-09-10 |
| AU2019205328A1 (en) | 2020-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020007081A (es) | Peptidos terapeuticos y metodos para tratar enfermedad relacionada con la autoinmunidad. | |
| Gao et al. | The potential role of IL-33/ST2 signaling in fibrotic diseases | |
| EA201291233A1 (ru) | Аналоги глюкагона | |
| PH12012502472A1 (en) | Glucagon analogues | |
| EA201590294A1 (ru) | Аналоги глюкагона | |
| PE20181338A1 (es) | Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones terapeuticas que los comprenden | |
| Mousa et al. | Advances in pharmacotherapy for primary biliary cirrhosis | |
| NZ754961A (en) | Growth differentiation factor 15 (gdf-15) constructs | |
| CL2020001113A1 (es) | Variantes e isoformas de anticuerpos con actividad biológica reducida. | |
| CY1119770T1 (el) | Νεο στελεχος bifidobacterium animalis υποειδ. lactis cect 8145 και χρηση αυτου για την αγωγη και/ή την προληψη του υπερβαρους και της παχυσαρκιας και των σχετικων παθησεων | |
| BR112016008540A2 (pt) | análogos de glucagon | |
| AR080027A1 (es) | Proteinas de union a cd127 | |
| PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
| AR080229A1 (es) | Proteinas de dominio de armazon de fibronectina que se unen a il -23 (interleucina 23) | |
| BR112014018210A2 (pt) | moléculas de ácido nucleico artificiais para expressão de proteína ou peptídeo melhorada | |
| MY188182A (en) | Acylated glucagon analogues | |
| CY1121332T1 (el) | Μiμhtiκα καλσιτονινης προς θεραπεια ασθενειων και διαταραχων | |
| EA201690494A1 (ru) | Ацилированные аналоги глюкагона | |
| MX2011006313A (es) | Analogos de glucagon. | |
| EP3421487A3 (en) | Peptides for modulating t-cell activity and uses thereof | |
| CL2020003293A1 (es) | Péptido que consiste en la secuencia de aminoácidos de seq id no: 42; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969) | |
| Salles et al. | Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failure | |
| PE20191529A1 (es) | Peptidos y metodos para el tratamiento de diabetes | |
| BR112017000710A2 (pt) | polipeptídeo isolado, polipeptídeo modificado de revestimento final isolado, composição de matéria, polipeptídeo de fusão isolado, composição farmacêutica, método de tratamento de uma doença inflamatória, uso do polipeptídeo isolado, polinucleotídeo isolado, estrutura de ácido nucleico, e método de determinação da potência de um lote do polipeptídeo isolado | |
| MX2022000032A (es) | Sialidasas recombinantes y métodos de utilización de las mismas. |